Multiple endocrine neoplasia type 2 prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of multiple endocrine neoplasia type 2}}'' | ! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of multiple endocrine neoplasia type 2}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left| '''Serum [[calcium]] level annually for people diagnosed with multiple endocrine neoplasia type 2A | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left| '''Serum [[calcium]] level annually for people diagnosed with multiple endocrine neoplasia type 2A''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual [[medullary thyroid cancer]] post [[thyroidectomy]] is detected by measurement of serum [[calcitonin]] annually''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual [[medullary thyroid cancer]] post [[thyroidectomy]] is detected by measurement of serum [[calcitonin]] annually''' | ||
Line 16: | Line 16: | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Parathyroid hormone]] level yearly for multiple endocrine neoplasia type 2A to detect [[hypoparathyroidism]]''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Parathyroid hormone]] level yearly for multiple endocrine neoplasia type 2A to detect [[hypoparathyroidism]]''' | ||
|- | |||
| style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/<ref>{{Cite journal| author = [[Jessica Marquard]] & [[Charis Eng]] | |||
| title = Multiple Endocrine Neoplasia Type 2 | |||
| year = 1993 | |||
| month = | |||
| pmid = 020301434 | |||
}}</ref> | |||
|} | |} | ||
<br><br><br><br><br><br> | <br><br><br><br><br><br> | ||
Revision as of 19:42, 28 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 prevention On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 prevention |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Secondary Prevention
Surveillance of multiple endocrine neoplasia type 2 | |
---|---|
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A | |
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually | |
Catacholamines, epinephrine and norepinephrine yearly for multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B patients to detect pheochromocytoma | |
Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years | |
Parathyroid hormone level yearly for multiple endocrine neoplasia type 2A to detect hypoparathyroidism | |
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1] |
References
- ↑ Jessica Marquard & Charis Eng (1993). "Multiple Endocrine Neoplasia Type 2". PMID 020301434.